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Objectives: The objectives of this study are to quantify endurance and respiratory function and better characterize
spectrum of symptoms and biochemical abnormalities in mucopolysaccharidosis IVA subjects.
Methods:MorCAPwas amulticenter, multinational, cross sectional study amended to be longitudinal in 2011. Each
study visit required collection of medical history, clinical assessments, and keratan sulfate (KS) levels.
Results: Data from the ﬁrst visit of 325 subjects (53% female) were available. Mean age was 14.5 years. Mean±SD
height z-scoreswere−5.6±3.1 as determined by the CDC growth charts.Mean±SD from the 6-minute-walk-test
was 212.6±152.2 m, revealing limitations in functional endurance testing, and 30.0±24.0 stairs/min for the
3-minute-stair-climb test. Respiratory function showed limitations comparable to MPS VI patients; mean±SD
was 1.2±0.9 l based on forced vital capacity and 34.8±25.5 l/min based on maximum voluntary ventilation.
Mean urinary keratan sulfate (uKS) was elevated for all ages, and negatively correlated with age. Higher uKS cor-
related with greater clinical impairment based on height z-scores, endurance and respiratory function tests. The
MPS Health Assessment Questionnaire reveals impairments inmobility and activities of daily living in comparison
to an age-matched control population.
Conclusions:MPS IVA is a multisystem disorder with a continuum of clinical presentation. All affected individuals
experience signiﬁcant functional limitations and reduced quality of life. Older patients have more severe exercise
and respiratory capacity limitations, and more frequent cardiac pathology illustrating the progressive nature of
disease.© 2013 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Themucopolysaccharidosis are a group of lysosomal storage disorders
(LSDs) in which deﬁcient enzyme activity results in impairment of the
degradation of glycosaminoglycans (GAGs) which, in turn, accumulateCA 94949, USA.
NC-ND license.in various tissues and organs. Morquio syndrome, including both MPS
IVA (Morquio A syndrome; OMIM 253000) and MPS IVB (Morquio B
syndrome; OMIM 253010), was ﬁrst described in 1929 [1]. Although
MPS IVB was originally thought to be the milder form of MPS IVA, these
were later demonstrated to be genetically distinct disorders each with a
different deﬁcient enzyme [2]. MPS IVA is characterized by deﬁciency of
N-acetylgalactosamine-6-sulfatase (GALNS), resulting in accumulation
of theGAGs keratan sulfate (KS) and chondroitin-6-sulfate (CS) in various
55P. Harmatz et al. / Molecular Genetics and Metabolism 109 (2013) 54–61tissues and organs [3–5]. Accumulation of KS leads to multi-systemic im-
pairments [5].
Information characterizing disease progression in MPS IVA is limited.
The progression of symptoms is variable, likely due to knowngenetic het-
erogeneity [5–8] with over 175 identiﬁed mutations in the GALNS gene
[9]. Life expectancy in patients with the rapidly progressing phenotype
ranges from the second to the third decade [10,11]. Rarely patients with
amore slowly progressing phenotype survive beyond 60 years.Mortality
is commonly due to cardiorespiratory or neurologic complications
[10,12–16]. To date, the management of MPS IVA has focused primarily
on palliative care to manage pain, infection and respiratory disease [14],
as well as on corrective orthopedic surgeries [17].
The wide phenotypic spectrum of MPS IVA [7,18,19] and limitations
in current urinary GAG (uGAG) testingmake it a challenging disorder to
diagnose [9,20]. Clinical suspicion is usually based on skeletal radio-
graphs revealing characteristic platyspondyly often with associated
thoracolumbar gibbus, cox valga with ﬂaring of the iliac wings, genu
valgum and dysplastic capital femoral epiphyses, failure to ossify the
lateral side of the upper tibial epiphysis and proximal pointing of the
metacarpals [6]. Suspicion ofMPS IVAmay be supported by quantitative
and/or qualitative testing of uGAG levels demonstrating increased
levels and presence of KS, but diagnosis requires conﬁrmation of
GALNS deﬁciency in WBC or ﬁbroblasts, or mutation analysis showing
the presence of pathogenic mutations in both alleles [9,21]. However,
patients with more slowly progressing disease may not present with
these obvious physical or radiologic manifestations and diagnosis may
not occur until later in life [4,6,22–25].
TheMorquio A Clinical Assessment Program (MorCAP) is the ﬁrst lon-
gitudinal study involving direct assessments of MPS IVA patients. This
multicenter, multinational, prospective study was initiated in 2008 to as-
sess and describe the spectrum of symptoms in this disorder including
growth, endurance, respiratory function, cardiac function, medical and
surgical history, as well as to measure select biochemical abnormalities
such as GAG levels, and inﬂammatory markers in MPS IVA patients. This
ﬁrst report will describe the design and methodology of this clinical
study as well as the cross-sectional baseline results of the ﬁrst 325 pa-
tients enrolled.
2. Methods
Originally, MorCAPwas a single visit, cross sectional study ofMPS IVA
patients without limitations on age or symptom severity with the ﬁrst
patient enrolling in 2008. To gain more detailed insight into the natural
history of MPS IVA, the study was amended to be longitudinal and was
approved as such at all sites in 2011. For inclusion to the study, individuals
had a conﬁrmeddiagnosis ofMPS IVA as documentedby eithermolecular
genetic testing or reduced GALNS activity as compared to the laboratory-
reported normal enzyme activity range for GALNS. Not all individuals
provided genetic diagnosis and consequently, this information is not
reported or analyzed. Exclusion criteria included previous HSCT or a con-
current disease or condition thatwould interferewith participation in the
study. Subjects remain in the study for up to 10 years unless the subject
enrolls in an interventional trial or the study is discontinued for clinical
or administrative reasons.
At the time of publication, baseline data from 325 patients were
available. At each study visit, a detailedmedical history, selected clinical
assessments, and physical examination are completed. The 6-minute
walk test (6-MWT) [26], 3-minute-stair-climb-test (3-MSCT) [27] and
respiratory function tests are performed according to published guide-
lines. Sites were provided with scheduling recommendations to allow
for adequate rest between effort-based procedures. The investigator
may opt to forgo assessments if clinically contraindicated. Additional
details of the schedule of assessments for the MorCAP study are avail-
able online in Supplemental Table 1.
The MPS Health Assessment Questionnaire (MPS HAQ) is a compre-
hensive clinical assessment instrument originally developed for MPS Ipatients, adapted for use inMPSVI patients [28] andnowused to evaluate
MPS IVA patients. Caregivers of patients b14 years of age complete the
MPS HAQ patient questions until the patient reaches 14 years; at
14 years of age, the patient completes the questionnaire independently.
Translations of the questionnaire have been provided to patients/
caregivers in their native language.
Urine KS and creatinine are measured from a ﬁrst morning void and
uKS values are normalized to creatinine levels. Measurements of uKS
are determined by a validated LC–MS/MS assay in which uKS measure-
ments are a measure of the sum of mono- and di-sulfated galactoseβ1
N-acetyl-D-glucosamine disaccharides (Galβ1–4GlcNAc(6S) and Gal(6S)
β1–4GlcNAc(6S)) generated after keratanase II digestion of KS in urine
with values normalized to creatinine excretion [29–32]. Biochemical
markers of bone and cartilage metabolism are collected from all subjects,
and will be measured in a random subset with other samples stored for
future analysis.
2.1. Statistical analysis
Baseline data from study visit 1 collected from clinical assessments
were summarized descriptively and graphically, including demo-
graphics, medical history, growth history, medications, vital signs and
ﬁndings from physical examinations. For 6-MWT, 3-MSCT, FVC and
MVV, p-values were calculated using an analysis of variance (ANOVA)
to compare low uKS versus high uKS groups, controlled for age group.
For each age group, p-values were also calculated to test equality of
low versus high uKS group.
Continuous variables were summarized using descriptive statistics
for mean, median, standard deviation, minimum, and maximum. For
subjects who were physically unable to perform the 6-MWT or the
3-MSCT, a value of zero was assigned. Count and percent were used
to summarize categorical variables.
3. Results
3.1. Demographics
Complete baseline results are currently available from 325 subjects
with MPS IVA representing a global sample including 10 countries.
Genders were nearly evenly distributed. The majority (79%) of subjects
were in the pediatric age group (18 years and younger);mean andmedi-
an ages were 14.5 years and 11.6 years (Table 1). Short stature was ap-
parent in the study population and affected male and female patients to
approximately an equal degree (Figs. 1A andB)withmean±SD(median;
min, max) height z-score for ≤18 years population of −5.10±2.85
(−5.23; −11.75, 1.93) and −7.59±3.04 (−8.94; −11.37, 0.50)
for >18 years population. Themean±SD (median;min,max) for height
is 101.2±15.8 (97.4; 77.8, 163.0)cm and length is 104.2±15.7 (101.0;
53.2, 156.5)cm (Table 1). Relative to previously reported height data in
MPS IVA patients [11], the range of subject heights in the current study
was generally similar, with the exception that many female subjects
had heights>90th percentile when measured against curves derived
from previously published data [11] (Figs. 1A and B).
Detailed medical histories, including chart review, were taken
from all patients. Reported complications impacted multiple systems in-
cluding musculoskeletal, nervous, respiratory, gastrointestinal, visual
and auditory systems, with all subjects reporting at least one medical
event, regardless of age. Musculoskeletal diagnoses were the most com-
mon category reported, with >90% of subjects reporting abnormal gait,
genu valgum, short stature, and/or short neck. Other common features
included joint laxity with stiffness and/or pain in >80% of subjects, and
joint contractures and subluxation in 52% and 47%, respectively. Spinal
abnormalities were commonly reported including kyphoscoliosis (85%),
odontoid dysplasia (65%), lumbar lordosis (56%), cervical spinal instabil-
ity (49%), and spinal disc disease (23%). Pectus carinatum was a near
Table 1
Demographics and baseline characteristics of MPS IVA patients.
Demographic
Number of patients 325
0–4 years 45
5–11 years 127
12–18 years 84
>18 years 69
Female N (%) 172 (52.9%)
Years of age mean (median; min, max) 14.5 (11.6; 1.1, 65.6)
Race
White 240 (73.8%)
Asian 51 (15.7%)
Black or African American 7 (2.2%)
Other 27 (8.3%)
Height by years mean (median; min, max) cm
0–4 (n=45) 88.5 (89.1; 77.8, 102.8)
5–11 (n=116) 102.0 (98.8; 81.9, 152.5)
12–18 (n=67) 108.1 (101.1; 86.0, 163.0)
>18 (n=58) 116.0 (104.9; 87.5, 180.2)
All subjects (n=286) 104.2 (98.9; 77.8, 180.2)
Length by years mean (median; min, max) cm
0–4 (n=32) 90.1 (90.8; 77.9, 98.8)
5–11 (n=90) 104.5 (102.2; 86.5, 153.0)
12–18 (n=72) 110.0 (103.7; 53.2, 156.5)
>18 (n=56) 114.8 (105.8; 85.2, 183.0)
All subjects (n=250) 106.6 (102.4; 53.2, 183.0)
Height z-score by age vs normal mean
(median; min, max) cm
0–4 (n=45) −2.09 (−2.28; −4.94, 1.93)
5–11 (n=116) −5.00 (−5.32; −9.51, 0.94)
12–18 (n=67) −7.27 (−7.41; −11.75, 0.26)
>18 (n=58)a −7.59 (−8.94; −11.37, 0.50)
All subjects (n=286) −5.60 (−5.60; −11.75, 1.93)
a Individuals >20 years are given z-scores standardized to 20 years.
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condition.
In their medical history, the majority of MPS IVA patients (71%)
reported surgical procedures; in patients ≥5 years, >70% experienced
at least one surgical procedure in each age group. Surgical interventions
reported in >10% of patients included ear ventilation tube insertion
(26%), adenoidectomy (22%), osteotomy (19%), spinal fusion (18%),
spinal decompression (14%) and tonsillectomy (11%) (Fig. 2). Just over
half (51%) of the subjects were reported to have nervous system disor-
ders, including 30% with cervical myelopathy, 14% with cervical cord
compression, and 13% with thoracolumbar cord compression. These dis-
orderswere reported in 36% (16/45) of the 0–4 years old group, 48% (61/
127) of 5–11 year olds, 58% (49/84) of 12–18 year olds, and 55% (38/69)
of the >18 years old group.
Concomitant medications were used by 211 (65%) subjects, with a
greater proportion of patients >18 years of age (71%) requiring concom-
itantmedications as compared to those in the≤18 years old group (63%).
Most commonly reported were medications used to treat pain and in-
ﬂammation; 79 (24%) of subjects used analgesics and of those 12 (4%)
used natural opium alkaloids, and 69 (21%), used anti-inﬂammatory
medications. Antibacterial medication, for treatment of infections such
as otitis media and pneumonia, was the next most common with 62
(19%); followed by medications used to treat obstructive airway disease
consisting of 44 (14%) of subjects. Additional details from patientmedical
histories are available online in Supplementary Table 2.
3.2. Clinical assessments
Limitations in endurance and respiratory function are presented in
Table 3. The 6-MWT was assessed in 316 patients; though the range
was wide (0–864 m), the mean and median were similar at 212.6±
152.2 and 224.0 m. Mean walk distance was 251.6±121.5 in
0–4 year olds (n=37), 232.5±140.1 in 5–11 year olds (n=127),
181.2±177.3 in 12–18 year olds (n=84), and 193.1±148.5 in>18 year olds (n=68). The 3-MSCT, performed by 274 evaluable
subjects, also showed a wide range of 0.0–115.0 stairs/min, with a
similar mean and median of 30.0±24.0 and 29.0 stairs/min. Most
patients had limited lung volumes, with a mean (median; min, max)
FVC in 261 patients of 1.2±0.9 (0.9, 0.2, 5.0)l; MVV in 237 evaluable
patients was 34.8±25.5 (26.6, 1.3–160.0)liters per minute.
The most common results from ECGs included the presence of sinus
tachycardia (n=14), sinus arrhythmias (n=11), and right or left bun-
dle branch block (n=11). Subjects were also reported with T wave ab-
normalities (n=7), right or left atrial enlargement (n=7), right or left
axis deviation (n=5), and right or left ventricular hypertrophy (n=4).
Echocardiograms showed cardiac valve regurgitation as a common
ﬁnding, with tricuspid regurgitation in 111 (34%), mitral regurgitation
in 82 (25%), aortic regurgitation in 63 (19%), and pulmonary regurgita-
tion in 46 (14%) subjects overall; incidence of cardiac valve stenosis was
not as prevalent but still present in each age group. While aortic valve
stenosis was relatively uncommon in the younger study population, in-
cidence increased with age, being reported in 16% of the patients
>18 years of age but in only 4% of patients≤18 years of age.Mitral ste-
nosis was reported in 15 (5%) subjects, 3 (1%) were reported with pul-
monary stenosis and 3 (1%) with tricuspid stenosis (Fig. 3).
3.3. Patient-reported outcomes
Mobility impairment was demonstrated by reported use of wheel-
chairs and walking aids in all age groups, with 45% reporting the use
of a wheelchair and 24% of a walking aid. Of these, 27% and 28% always
required their wheelchair or walking aid, respectively. Impairment in
activities of daily living such as grooming, use of ﬁngernail clippers
and ability to brush hair and independently wash was also reported
(online Supplementary Table 3).
3.4. Levels of keratan sulfate
Keratan sulfate concentrations were measured in patient samples of
urine and plasma. As measurable plasma KS concentrations may overlap
between Morquio A and unaffected individuals [32,33], urine KS levels
more consistently distinguish MPS IVA from unaffected individuals;
hence, uKS levels are reported for the MorCAP population.
UrineKS levelswere available from310 individualswith valuesmiss-
ing for the other 15 individuals; mean±SD (median; min, max) uKS
(expressed as μg/mg creatinine) was 36.4±28.4 (31.2; 0.9, 222.7), and
was higher in patients ≤18 years when compared to patients
>18 years (Table 2). This decrease in uKS may reﬂect the expected de-
crease in cartilage formation as patients reach puberty and bone growth
centers close [33]. In order to account for age-related decrease, uKS
cut-off levels were identiﬁed based on correlation between uKS and
6-MWT with locally weighted scatterplot smoothing. Low uKS was de-
ﬁned as≤20 μg/mg for subjects≤18 years old and≤10 μg/mg for sub-
jects >18 years old. On average, subjects with high uKS demonstrated
greater clinical impairment, as measured by height and length z-scores,
and endurance and respiratory function tests, than those with low uKS
levels (Table 3). Fig. 4 demonstrates that pediatric patientswith the low-
est uKS levels have the tallest average height, those with mid-range uKS
havemid-range height and those patients with the highest uKS have the
shortest or lowest heights. Both pediatric and adult subjects with low
uKS on average had closer to normal height, longer walk distance, great-
er stair climb result, and greater FVC and MVV volumes (Table 3).
3.5. Discussion/conclusion
This study is theﬁrst to deﬁne the natural history ofMPS IVA through
direct clinical observation and testing in a large number of affected indi-
viduals, although patient-reported outcomes describing disease mani-
festations have been previously reported by the International Morquio
Organization (IMO) [34]. Study data will assist in evaluation of clinical
Fig. 1. A and B. Absolute height (cm) of MorCAP participants at baseline visit compared to published growth curves for MPS IVA [11] and the CDC normal growth chart.
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sion and efﬁcacy of potential treatments. With 325 patients enrolled
from 10 countries, MorCAP is estimated to represent approximately 10%
of the global MPS IVA patient population based on an estimated average
incidence of 1:250,000 births [35] and world birth rates in developing
countries, providing the ability to identify general conclusions about
symptoms and disease progression in this patient population.
While the heterogeneity ofMPS IVA is reﬂected by the varied clinical
presentation of study subjects, on average and consistent with reports
in the literature, data demonstrates signiﬁcant impairment across mul-
tiple domains including growth [5,6,11–14,34], endurance andmobility[12–14,17,34,36], respiratory function [5,10,14–16,34], and the impact
of burden of illness on quality of life [14,34]. In addition, clinical impair-
ments are more severe in older age groups in general, suggesting pro-
gression of clinical symptoms with age [14,34,36].
Growth and ﬁnal height are commonly used as indicators of disease
severity inMPS IVApatients and are negatively correlatedwith uKS levels
(Fig. 4). Although longitudinal data will provide additional insights into
the impact of Morquio A on height, baseline height z-scores revealed in-
creasing abnormality with age, suggesting that in many patients, growth
slows or stops in early childhood (Fig. 4). Similar to previous ﬁndings
[5,11], growth in infancy appears normal, but decreases signiﬁcantly
Fig. 2. Incidence of selected surgical procedures for all subjects.
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(Figs. 1A and B). The signiﬁcantly impacted height in the MorCAP study
population (Table 1) reinforces the assertion of the severe skeletal impli-
cations of MPS IVA in all clinical phenotypes [5,6,11,17,34]. These severe
skeletal manifestations may impact the accuracy of measuring growth in
MPS IVA patients as progressively worsening muscle weakness or bone
abnormalities can negatively impact patient ability to be measured in a
standing position, thus requiring measurement by length. Although a
high correlation exists betweenheight and lengthmeasurements, change
in measurement may cause a 1–2 centimeter variance [37].
Plasma KS and uKS levels are hypothesized to be reﬂective of the
total body storage of KS [29]. Urine KS levels of 36.4 (0.9, 222.7) μg/mg
(Table 2) in the MorCAP study population were elevated as compared
to reported norms of approximately 1.94 (0.47, 3.90) μg/mg in the unaf-
fected population [38]. No gender differences in uKS levels were ob-
served. Higher uKS levels were found to be associated with a greater
degree of impairment in several clinical outcome measures (6-MWT,
3-MSCT, height, FVC and MVV) across age groups (Table 3), in spite of
expected age-related decrease in uKS levels associated with closure of
growth plates. This suggests that higher uKS levels may be indicative
of a more rapidly progressive end of the disease spectrum; however, it
is difﬁcult to classify patients only on baseline uKS levels. Additional
longitudinal data will provide a more deﬁnitive prognosis for the study
population.
Endurance measures are important indicators of functional im-
pairment in individuals with progressive diseases [39]. The 6-MWT,Fig. 3. Incidence of cardiac valvea submaximal exercise test widely used tomeasure endurance and ﬂex-
ibility in a range of patients [39–41] including those withMPS disorders
[39,42], and the 3-MSCT evaluate the effort required by the cardiovas-
cular, pulmonary and/ormusculoskeletal systems to perform anactivity
[39,43]. The results of the 6-MWT and 3-MSCT reveal impairment in the
MPS IVA population regardless of age group, suggesting that thesemea-
sures are appropriate to assess changes across the entire study popula-
tion. The overallmean (SD) 6-MWTdistance of 212 (152) meters (m) is
signiﬁcantly reduced when compared to the lower limit of normal,
reported as ranging from 470–664 m for healthy individuals aged
4–16 years [44,45] and approximately 500–580 m for healthy adults
[26]. Although no normative data is available for the 3-MSCT, the stair
climb rate of 29 (24)stairs/min reported in MPS IVA patients here
shows more signiﬁcant impairment when compared to the baseline
stair climb rate of 50±29.5 in theMPS VI population [42]. Although dif-
ferences in stair height and stairwell conﬁguration prohibit standardi-
zation, the 3-MSCT was adapted from the 3-minute step test, which is
a validated measure of respiratory function for children with cystic
ﬁbrosis, and takes the severe physical limitations of children with MPS
VI into account [27].
Impairments in both the 6-MWT and 3-MSCT correlate with uKS
levels, although less impairment was observed with the older age
group in the results of the 6-MWT in the low uKS group (Table 3). How-
ever, even the lowuKS adult subjectswho showed the least impairment
in the 6-MWT at 265.7 m reveal signiﬁcant impairment (Table 3) when
compared to the unaffected adult population [38], reinforcing the valueabnormalities by age group.
Table 2
Urine KS (μg/mg creatinine) by age group in MPS IVA subjects.
uKS group 0–4
(n=45)
5–11
(n=127)
12–18
(n=84)
Over 18
(n=69)
n 39 124 82 65
Mean (SD) 56.9 (25.1) 46.8 (30.6) 30.5 (20.4) 11.9 (8.1)
Median 52.7 43.3 28.1 10.1
Min, max 19.9, 112.0 4.8, 222.7 1.7, 110.3 0.9, 41.6
p-Valuesb0.0001 for all pairwise comparisons of mean uKS by age groups, except
p-value=0.0230 for 0–4 years vs. 5–11 year old groups.
p-Value for overall comparison b0.0001.
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being associatedwith uKS levels, changes in endurancemeasures corre-
late with respiratory function (Table 3) and disease severity [39], and
have been associated with increased severity of exertional dyspnea,
tachycardia, tachypnea and orthopenia [28]. Firm conclusions regarding
the prognostic value of uKS will require longitudinal data collection to
deﬁnitively determine associations between this biomarker and clinical
outcomes.
In the absence of a standard curve to evaluate respiratory function
for patients with MPS diseases that reﬂects height, weight and thoracic
malformations, comparisons of FVCmeasures to standard norms are rel-
atively meaningless [28]. However, FVC and MVV impairments were
comparable to ﬁndings with other MPS diseases [28,46]. Respiratory
function impairment was demonstrated in all age groups by severely
limited volumes in FVC and MVV (Table 3) and was correlated with
uKS levels (Table 3). The limitation in MVV in this study population
not only indicates reduced lung volumes, but also suggests a reduced
ability to carry out the work of breathing. This may reﬂect limitations
in strength of the diaphragm and/or intercostal muscles as well as limit-
ed chest wall compliance [47] and airway obstruction [14,15,47-49]. It is
likely that the low FVC volumes are related to reduced height [14,28],
malformed thorax, and reduced patency of the upper airway that isTable 3
Endurance and pulmonary function in MPS IVA subjects by uKS (μg/mg creatinine) and age
>18 years old.
Age≤18 years
Low uKS group
(n=44)
High uKS group
(n=201)
Missing uKS
(n=1)
All
(n=2
6-MWT (m)
p=0.0013a
p=0.1215b
N 45 195 8 248
Mean (SD) 255.4 (183.7) 216.5 (143.1) 45.1 (68.6) 218.0
Median 264.0 234.9 18.5 234.0
Min, max 0.0, 801.3 0.0, 864.0 0.0, 200.6 0.0, 86
3-MSCT (steps/min)
p=0.0085a
p=0.1948b
N 42 165 8 215
Mean (SD) 36.6 (28.0) 31.1 (23.5) 15.5 (16.4) 31.6 (
Median 34.2 31.0 12.7 31.0
Min, max 0.0, 115.0 0.0, 112.4 0.0, 43.5 0.0, 11
FVC (L)
pb0.0001a
pb0.0001b
N 43 148 4 195
Mean (SD) 1.9 (1.0) 0.9 (0.4) 0.6 (0.1) 1.1 (0
Median 1.7 0.8 0.5 0.9
Min, max 0.5, 4.5 0.2, 2.7 0.5, 0.7 0.2, 4.
MVV (L/min)
pb0.0001a
pb0.0001b
N 40 134 4 178
Mean (SD) 56.1 (29.6) 25.7 (13.1) 19.4 (4.9) 32.4 (
Median 51.8 24.0 18.6 25.5
Min, max 9.7, 119.0 1.3, 90.0 14.5, 25.8 1.3,11
a p-Value for comparing uKS groups controlling for age.
b p-Value comparing equality of low versus high uKS group.characteristic of MPS IVA disease [14]; there is no evidence in the liter-
ature that GAG accumulation in the lungs interferes directly with respi-
ratory function. A signiﬁcant proportion of morbidity and mortality in
MPS IVA is related to the respiratory system [14]; this is reﬂected by
the number of subjects reporting respiratory system complications in
medical history and the common use ofmedications to treat respiratory
disorders.
Cardiac involvement was frequently found in the MorCAP popula-
tion (Fig. 3), despite the lack of literature to suggest that this condition
is commonly associated with MPS IVA [5,50]. The assertion of the
underreporting of cardiac involvement in MPS IVA [14] is reinforced
by the results of the ECG ﬁndings coupled with the reported incidence
of regurgitation and stenosis in all ages of theMorCAP study population.
Regurgitation was more commonly found than stenosis [14,50–53],
with tricuspid regurgitation most commonly reported in the MorCAP
population, consistent with the literature [50–52]. Although further re-
search and longitudinal data are needed to further elucidate the cause of
this ﬁnding, as cardiac disease is always progressive [50] this baseline
data reinforces recommendations for frequent cardiac assessments
[14].
Quality of life forMPS IVA patients is signiﬁcantly impacted by disease
progression and manifestations regardless of clinical phenotype [14]
(online Supplementary Table 3). Patients had frequent infections as
compared to unaffected individuals. Vision and hearing impairments
were also reported. The use of painmedications in all age categories is in-
dicative of the pain associatedwith tasks of daily living for all individuals
with MPS IVA; the increased use of pain medication with age suggests
increased pain with age. More than half of theMorCAP study population
required awheelchair orwalking aid formobility. Almost 75% of patients
b12 years of age and more than 95% of patients in the ≥12 years age
groups required surgical or medical interventions, which carry a high
risk for surgical and anesthetic complications due to GAG accumulation
obstructing airways as well as skeletal abnormalities, risk of spinal cord
injury, frequent lung infections and restrictive lung and cardiac diseasesgroup. Low uKS is ≤20 μg/mg for subjects ≤18 years old and ≤10 μg/mg for subjects
Age>18 years
56)
Low uKS group
(n=32)
High uKS group
(n=33)
Missing uKS
(n=4)
All
(n=69)
p=0.0002b
32 33 3 68
(153.2) 265.7 (140.9) 136.6 (125.9) 40.0 (69.3) 193.1 (148.5)
311.2 100.0 0.0 206.0
4.0 0.0, 510.0 0.0, 418.6 0.0, 120.0 0.0, 510.0
p=0.0016b
26 31 2 59
24.5) 34.0 (20.6) 16.4 (19.3) 15.0 (21.2) 24.1 (21.5)
34.9 6.3 15.0 23.3
5.0 0.0, 89.6 0.0, 63.2 0.0, 30.0 0.0, 89.6
pb0.0001b
32 33 1 66
.7) 2.1 (1.3) 0.8 (0.4) 3.0 (NA) 1.5 (1.1)
1.80 0.80 3.00 1.00
5 0.5, 5.0 0.3, 2.5 3.0, 3.0 0.3, 5.0
pb0.0001b
28 30 1 59
22.1) 59.2 (37.5) 24.2 (10.9) 98.7 (NA) 42.1 (32.8)
44.0 22.1 98.7 31.5
9.0 13.7, 160.0 6.3, 56.7 98.7, 98.7 6.3, 160.0
Fig. 4. Height z-score for MPS IVA subjects (aged 18 years and younger) by uKS Levels (μ/mg creatinine).
60 P. Harmatz et al. / Molecular Genetics and Metabolism 109 (2013) 54–61[15,34]. Spinal fusion and decompression surgeries were both reported
in >10% of the MorCAP study population while instability of the spinal
region places patients at risk for spinal injury [10]. Combined, these
ﬁndings suggest signiﬁcant burden of the disease across all ages and
phenotypes of MPS IVA.
TheMorquio A Clinical Assessment Program (MorCAP) is the ﬁrst lon-
gitudinal study involving direct assessments ofMPS IVApatients. Baseline
data provides insight into the clinical presentation and signiﬁcant burden
of illness associated with MPS IVA regardless of age and clinical pheno-
type. All individuals with MPS IVA develop progressively severe clinical
manifestations, although potentially later in life for those individuals
withmore slowly progressive disease. Characterization of clinical impair-
ments across a large subject population is expected to improve under-
standing of the disease and to potentially facilitate better management.
While further analyses of patients returning for longitudinal annual as-
sessments will provide insight into the natural history of MPS IVA, the
current cross-sectional data reported here demonstrates the progressive
worsening of the disorder with age and offers guidance for clinical trial
outcomes, the diagnostic process, and the ongoing management of MPS
IVA patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ymgme.2013.01.021.
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